Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 38Colorectal Neoplasms 18Small Cell Lung Carcinoma 8Neoplasms 8Stomach Neoplasms 7Neoplasm Metastasis 5Biliary Tract Neoplasms 5Sarcoma, Ewing 4Rhabdomyosarcoma 4Recurrence 4Osteosarcoma 4Rectal Neoplasms 3Ovarian Neoplasms 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Solid Tumor 2Neuroblastoma 2Nasopharyngeal Carcinoma 2Metastatic Pancreatic Adenocarcinoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Wilms Tumor 1Weight Loss 1Somatostatinoma 1Solid Tumor Cancer 1Small Cell Lung Cancer Extensive Stage 1

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Borderline Resectable Pancreatic Cancer × irinotecan sucrosofate × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡